Sydnexis Announces New Data from Phase 3 STAR Trial of SYD-101 Presented at 2026 AAPOS Annual Meeting

DEL MAR, Calif.--(BUSINESS WIRE)--Sydnexis, Inc., a biopharmaceutical company focused on developing a novel low-dose atropine formulation to treat pediatric progressive myopia (PPM), today announced new data from comprehensive subgroup analyses from the Phase 3 Study of Atropine for the Reduction of Myopia Progression (STAR) trial of SYD-101. The data were presented during an oral session at the 51st Annual Meeting of the American Association for Pediatric Ophthalmology and Strabismus (AAPOS) i